CanniControl Sponsoring Research and Collaborating with Researchers from the College of Education at Florida Atlantic University to Study Marijuana Addiction and Withdrawal
Weedless.org’s parent company CanniControl has entered into a Sponsored Research Agreement (SRA) with Florida Atlantic University (FAU). As part of the collaboration, researchers from the college of Education at FAU have initiated a non-clinical research study, Survey of Cannabis Users Who Have Tried to Reduce Their Use.
Persons interested in learning about the study, or participating, can find more details, here: https://www.weedless.org/research/.
“According to recent Gallup polls, 55 million Americans identify as active cannabis users and nearly 1in 4 of young adults consumed cannabis in the past month,” said Brian S. Canfield, Ed.D., a Professor in the College of Education at FAU and a member of CanniControl’s Scientific Advisory Board. “With widespread use comes widespread abuse and dependence, which is more severe than many recognize. We are glad to be collaborating with CanniControl on research that seeks to advance our understanding of the needs of chronic cannabis users.”
“Many daily cannabis users are interested in quitting or cutting down, but struggle to do so. Our research aims to identify barriers these individuals encounter during attempts at abstinence,” said Paul R. Peluso, Ph.D., a Professor in the College of Education at FAU and a member of CanniControl’s Scientific Advisory Board. “We have enrolled the first participants in the current study and are advancing other research initiatives to evaluate novel approaches to helping what we believe to be an underserved population of chronic cannabis users desiring guidance and support.”
While most individuals can use cannabis without harm, approximately 1 in 10 will develop cannabis use disorder (DSM-5), also referred to as cannabis abuse, dependence, or addiction. For these individuals, abstinence and reduction attempts are generally short-lived, with most attempts to stop or reduce lasting less than a week. Currently, there are no FDA-approved pharmacotherapies available for cannabis use disorder and most daily cannabis users do not seek professional help.